We have recently developed the Prediction of MLH1 and MSH2 mutations model (PREMM1,2), a clinical prediction rule designed to be used by healthcare providers to estimate the probability that an individual carries a mutation in the MLH1 or MSH2 mismatch repair genes (Balmana et al. JAMA 2006). PREMM1,2 was developed and subsequently validated in over 2000 patients who were at elevated risk of Lynch Syndrome and undergoing genetic evaluation. Lynch Syndrome, also known as hereditary non- polyposis colorectal cancer (HNPCC), is the most common hereditary colon cancer syndrome, and also increases the risk for several extracolonic cancers. MLH1 and MSH2 mutations are the most common underlying cause. In a subset of families, mutations are found in a third mismatch repair gene, MSH6, and lead to a milder phenotype. Tumors in patients with Lynch syndrome demonstrate microsatellite instability (MSI) and can show loss of expression of the affected mismatch repair gene, which may be detected by immunohistochemical analysis (IHC). In addition to PREMM1,2, two other prediction models have recently been developed, and a variety of clinical guidelines are also available for the clinician as risk assessment tools. The performance characteristics of the available models and clinical guidelines have not been compared with another, nor is it known which approach, or combination of approaches, is the most cost-effective method of identifying and managing patients with Lynch Syndrome. As an expansion of our prior work, the aims of this project are (1) To validate PREMM1,2 in several existing U.S. and international colon cancer registries, including the Colon Cancer Family Registries (CCFR), EPICOLON, and Ohio State cohorts;(2)To expand the PREMM1, 2 model to include prediction of MSH6 mutation carriers;(3) To develop a version of the PREMMM1,2,6 model that (i) allows for the incorporation of information on MSI and IHC for further refinement of the predicted probabilities of a germline mutation, and (ii) makes gene-specific predictions based on clinical history, MSI and IHC results;(4)To compare the PREMMM1,2,6 , Barnetson, MMRPro models in (i) their ability to distinguish mutation carriers from non-carriers;(ii) different settings (population or clinic-based cases);(iii) a population-based series of endometrial cancer cases;and (5) To perform a cost-effectiveness analysis to define the role of the PREMM1,2,6 model and other clinical and molecular strategies for identification of individuals at risk of Lynch syndrome.

Public Health Relevance

The results of this effort will achieve several goals of PA-07-021. It will (i) lead to a comprehensive clinical and public health approach to the identification and management of patients with hereditary colon cancer;(ii) allow for more precise estimation of the specific tumors associated with each MMR gene and therefore more targeted cancer screening and prevention approaches;and (iii) bring together investigators from diverse backgrounds, including geneticists, molecular epidemiologists, statisticians and clinicians, who will work together, share existing data and expertise to address research questions that could not be answered in isolation.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA132829-04
Application #
8121649
Study Section
Epidemiology of Cancer Study Section (EPIC)
Program Officer
Shelburne, Nonniekaye F
Project Start
2008-09-30
Project End
2013-08-31
Budget Start
2011-09-01
Budget End
2013-08-31
Support Year
4
Fiscal Year
2011
Total Cost
$379,100
Indirect Cost
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Kastrinos, Fay; Uno, Hajime; Ukaegbu, Chinedu et al. (2017) Development and Validation of the PREMM5 Model for Comprehensive Risk Assessment of Lynch Syndrome. J Clin Oncol 35:2165-2172
Yurgelun, Matthew B; Kulke, Matthew H; Fuchs, Charles S et al. (2017) Cancer Susceptibility Gene Mutations in Individuals With Colorectal Cancer. J Clin Oncol 35:1086-1095
Kastrinos, Fay; Ojha, Rohit P; Leenen, Celine et al. (2016) Comparison of Prediction Models for Lynch Syndrome Among Individuals With Colorectal Cancer. J Natl Cancer Inst 108:
Inra, Jennifer A; Steyerberg, Ewout W; Grover, Shilpa et al. (2015) Racial variation in frequency and phenotypes of APC and MUTYH mutations in 6,169 individuals undergoing genetic testing. Genet Med 17:815-21
Yurgelun, Matthew B; Allen, Brian; Kaldate, Rajesh R et al. (2015) Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome. Gastroenterology 149:604-13.e20
Kastrinos, Fay; Steyerberg, Ewout W (2015) Family matters in lynch syndrome. J Natl Cancer Inst 107:
Everett, Jessica N; Raymond, Victoria M; Dandapani, Monica et al. (2014) Screening for germline mismatch repair mutations following diagnosis of sebaceous neoplasm. JAMA Dermatol 150:1315-21
Kastrinos, Fay; Steyerberg, Ewout W; Balmaña, Judith et al. (2013) Comparison of the clinical prediction model PREMM(1,2,6) and molecular testing for the systematic identification of Lynch syndrome in colorectal cancer. Gut 62:272-9
Kastrinos, Fay; Balmaña, Judith; Syngal, Sapna (2013) Prediction models in Lynch syndrome. Fam Cancer 12:217-28
Mercado, Rowena C; Hampel, Heather; Kastrinos, Fay et al. (2012) Performance of PREMM(1,2,6), MMRpredict, and MMRpro in detecting Lynch syndrome among endometrial cancer cases. Genet Med 14:670-80

Showing the most recent 10 out of 11 publications